Ryoncil Sales Hit $30.3M in March Quarter, Nearing $100M Since Launch
MESO sits 55% above its 52-week low of $9.61.
Summary
Mesoblast announced strong commercial performance for its FDA-approved product, Ryoncil, reporting net sales of US$30.3 million for the March quarter. This brings the total revenue generated by Ryoncil since its launch to nearly US$100 million, demonstrating successful market penetration and adoption. The impressive sales figures are a material positive for Mesoblast, strengthening its balance sheet and providing capital to support label extension and late-stage pipeline programs. Investors will be watching for further details on the company's growth strategy for Ryoncil and its broader product pipeline at its upcoming R&D Day this week.
At the time of this announcement, MESO was trading at $14.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $9.61 to $21.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.